ArticleInfectious medicine2026
Unequal patterns of tuberculosis in women of reproductive age: Insights from the Global burden of disease study 2021.
Article in Infectious medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) remains a major global cause of mortality and is a leading cause of death among women of reproductive age (WRA). Untreated TB in this population endangers both maternal and neonatal health, yet the age-stratified burden and the shifting distribution of drug-resistant tuberculosis remain poorly defined in global health agendas. This study aims to employ data from the 2021 Global Burden of Disease Study to systematically evaluate the global, regional, and age-specific burden of TB among WRA, to delineate temporal trends in drug-resistant TB, and to assess associated risk factors using standardized estimation methods. Methods: Leveraging data from the Global Burden of Disease Study 2021 covering 204 countries and territories, we systematically assessed TB burden in WRA aged 15-49 years from 1990 to 2021. We analyzed age-standardized incidence, prevalence, mortality, and disability-adjusted life years across socio-demographic index (SDI) regions, TB subtypes, and risk factors. Projections to 2030 were generated using autoregressive integrated moving average models. Results: Between 1990 and 2021, the global prevalence and incidence of TB among WRA declined significantly. However, this decline was uneven across age groups, disease types, and regions. TB incidence peaked in women aged 15-24 years, while mortality and disease burden were highest among those aged 45-49 years. Drug-resistant tuberculosis was most prominent in the 25-29 age group. Geographically, sub-Saharan Africa remained the core of the global TB burden, with BRICS (Brazil, Russia, India, China, South Africa) countries carrying significantly higher burdens than G7 countries. Risk attribution patterns revealed a shift from behavioral to metabolic drivers, with high body mass index emerging as the leading risk factor in high-SDI regions. Middle-SDI regions showed a combination of metabolic and behavioral risks, while metabolic factors remained dominant in low-SDI settings. Drug-susceptible tuberculosis was primarily linked to smoking and malnutrition, whereas drug-resistant tuberculosis was increasingly associated with metabolic dysfunction. Conclusions: Despite global declines in TB prevalence and incidence among WRA, stark disparities persist. The age-stratified rise in drug-resistant TB, particularly in resource-constrained regions, underscores the need for targeted, gender-responsive interventions that integrate infectious disease control with metabolic health strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.